Michael O Chaney1, W Blaine Stine, Tyler A Kokjohn
1Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
This study explored how the receptor RAGE interacts with amyloid beta (Abeta) peptides in Alzheimer's disease. Using atomic force microscopy and computational modeling, the researchers found that the N-terminal domain of RAGE can inhibit Abeta aggregation. They observed that soluble RAGE dimers form a positively charged well that binds to the negatively charged N-terminal domain of dimeric Abeta. These findings suggest a structural mechanism by which RAGE may modulate Abeta accumulation. The study highlights the importance of understanding RAGE's role in both inhibiting and promoting Abeta-related processes. The results were based on detailed imaging and modeling techniques to explore molecular interactions.
Area of Science:
Background:
Alzheimer's disease involves accumulation of amyloid beta (Abeta) peptides that influence receptor activity. These peptides interact with RAGE, a receptor linked to inflammation. While soluble RAGE inhibits Abeta aggregation, membrane-bound RAGE promotes inflammation. Prior research has shown that RAGE exists in both soluble and membrane-bound forms. The role of RAGE in Abeta aggregation remains unclear. Atomic force microscopy has revealed interactions between RAGE and Abeta. Computational modeling has been used to explore these interactions further. This gap motivated the use of advanced imaging and modeling techniques. That uncertainty drove the investigation into structural details of RAGE-Abeta interactions.
Purpose Of The Study:
This study aimed to clarify how RAGE interacts with Abeta to influence aggregation and inflammation. The specific problem is the dual role of RAGE in both inhibiting and promoting Abeta accumulation. Understanding these interactions could inform therapeutic strategies. The researchers sought to determine the structural basis of RAGE-Abeta binding. They used atomic force microscopy to observe physical interactions. Computational modeling was employed to predict binding mechanisms. The study focused on the N-terminal domain of RAGE. This approach allowed for detailed analysis of RAGE-Abeta interactions.
The N-terminal domain of RAGE creates a positively charged well that binds to the negatively charged N-terminal domain of dimeric Abeta.
Soluble RAGE dimers inhibit Abeta aggregation, while membrane-bound RAGE promotes inflammation via NF-kappaB activation.
To observe the physical interactions between RAGE and Abeta at the molecular level and confirm the inhibitory effect of RAGE.
The dimeric structure forms a binding site that accommodates the N-terminal domain of dimeric Abeta, influencing aggregation.
Main Methods:
The researchers used atomic force microscopy to observe RAGE-Abeta interactions. They analyzed the N-terminal domain of RAGE for its effect on Abeta aggregation. Computational chemistry algorithms were applied to model structural interactions. These models predicted the electrostatic properties of RAGE and Abeta. The study compared soluble and membrane-bound RAGE configurations. The team examined the impact of RAGE dimers on Abeta polymerization. They assessed how charge distribution affects binding affinity. This approach combined imaging and modeling to explore molecular mechanisms.
Main Results:
Atomic force microscopy showed that RAGE's N-terminal domain inhibits Abeta aggregation. This inhibition occurs even during prolonged incubation periods. Computational models revealed a positively charged well in dimeric RAGE. This well accommodates the negatively charged N-terminal domain of dimeric Abeta. The study found that soluble RAGE dimers form a stable binding site for Abeta. The electrostatic interaction between RAGE and Abeta was confirmed through modeling. These findings suggest a structural basis for RAGE's inhibitory effect. The results support the idea that RAGE can modulate Abeta aggregation.
Conclusions:
The study suggests that RAGE-Abeta interactions depend on structural configurations. Soluble RAGE dimers may inhibit Abeta aggregation through electrostatic binding. The N-terminal domain of RAGE plays a key role in this process. The findings support the use of computational modeling to predict binding mechanisms. Atomic force microscopy confirmed these interactions at the molecular level. The results align with prior knowledge about RAGE's dual role in inflammation. The study highlights the importance of structural details in RAGE function. These conclusions are based on the authors' analysis of imaging and modeling data.
Atomic force microscopy and computational modeling were used to assess structural and electrostatic interactions.
The study suggests that structural details of RAGE-Abeta interactions may inform therapeutic strategies targeting aggregation.